新型药物、治疗策略及肺动脉高压治疗的未来方向。
New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension.
机构信息
Johns Hopkins University, Division of Pulmonary and Critical Care Medicine, Baltimore, MD, United States.
Federico II University, Department of Translational Medical Sciences, Naples, Italy.
出版信息
Curr Med Chem. 2019;26(16):2844-2864. doi: 10.2174/0929867325666180201095743.
Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.
尽管肺动脉高压（PAH）的治疗最近取得了进展，但这种疾病的预后仍然非常差。在这篇综述中，我们讨论了已有的作用机制（马西替坦）、创新靶点（利奥西呱和塞立西帕）的新药以及初始联合治疗的新型治疗方法在 PAH 治疗中的应用。其次，我们描述了新的潜在信号通路和有前途的治疗 PAH 的研究药物。
Zotero 插件